News | July 23, 2025
Lonza reports 19% growth in sales in H1
Upgrades 2025 full-year CDMO sales and margin outlook
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
The company showcased three core programs developed through this platform
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Annual EBITDA margin expands by 170 basis points
Akums invested Rs. 272 crore in capital expenditure during FY25
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Subscribe To Our Newsletter & Stay Updated
